Journal ArticleDOI
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
Henryk Barthel,Hermann-Josef Gertz,Stefan Dresel,Oliver Peters,Peter Bartenstein,Katharina Buerger,Florian Hiemeyer,Sabine M Wittemer-Rump,John Seibyl,Cornelia Reininger,Osama Sabri +10 more
TLDR
The diagnostic efficacy of the scans was established in differentiating between patients with probable disease and age-matched healthy controls on the basis of neocortical tracer uptake pattern 90-110 min post-injection and the sensitivity and specificity of florbetaben (¹⁸F) PET was assessed.Abstract:
Summary Background Imaging with amyloid-β PET can potentially aid the early and accurate diagnosis of Alzheimer's disease. Florbetaben ( 18 F) is a promising 18 F-labelled amyloid-β-targeted PET tracer in clinical development. We aimed to assess the sensitivity and specificity of florbetaben ( 18 F) PET in discriminating between patients with probable Alzheimer's disease and elderly healthy controls. Methods We did a multicentre, open-label, non-randomised phase 2 study in 18 centres in Australia, Germany, Switzerland, and the USA. Imaging with florbetaben ( 18 F) PET was done on patients with probable Alzheimer's disease (age 55 years or older, mini-mental state examination [MMSE] score=18–26, clinical dementia rating [CDR]=0·5–2·0) and age-matched healthy controls (MMSE ≥28, CDR=0). Our primary objective was to establish the diagnostic efficacy of the scans in differentiating between patients with probable disease and age-matched healthy controls on the basis of neocortical tracer uptake pattern 90–110 min post-injection. PET images were assessed visually by three readers masked to the clinical diagnosis and all other clinical findings, and quantitatively by use of pre-established brain volumes of interest to obtain standard uptake value ratios (SUVRs), taking the cerebellar cortex as the reference region. This study is registered with ClinicalTrials.gov, number NCT00750282. Findings 81 participants with probable Alzheimer's disease and 69 healthy controls were assessed. Independent visual assessment of the PET scans showed a sensitivity of 80% (95% CI 71–89) and a specificity of 91% (84–98) for discriminating participants with Alzheimer's disease from healthy controls. The SUVRs in all neocortical grey-matter regions in participants with Alzheimer's disease were significantly higher (p r −0·27 to −0·33, p≤0·021). APOE ɛ4 was more common in participants with positive PET images compared with those with negative scans (65% vs 22% [p=0·027] in patients with Alzheimer's disease; 50% vs 16% [p=0·074] in healthy controls). No safety concerns were noted. Interpretation We provide verification of the efficacy, safety, and biological relevance of florbetaben ( 18 F) amyloid-β PET and suggest its potential as a visual adjunct in the diagnostic algorithm of dementia. Funding Bayer Schering Pharma AG.read more
Citations
More filters
Journal ArticleDOI
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
TL;DR: The A β-dependent and Aβ-independent mechanisms that link Apo-E4 status with AD risk are discussed, and how to design effective strategies for AD therapy by targeting ApO-E is considered.
Journal ArticleDOI
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.
Christiane Reitz,Richard Mayeux +1 more
TL;DR: An overview of the epidemiology of AD is provided, the biomarkers that may be used for risk assessment and in diagnosis are reviewed, and suggestions for future research are given.
Journal ArticleDOI
Plasma phospholipids identify antecedent memory impairment in older adults
Mark Mapstone,Amrita K. Cheema,Massimo S. Fiandaca,Xiaogang Zhong,Timothy R. Mhyre,Linda MacArthur,William J. Hall,Susan G. Fisher,Derick R. Peterson,James M Haley,Michael Nazar,Steven A. Rich,Dan J Berlau,Carrie B. Peltz,Ming Tan,Claudia H. Kawas,Howard J. Federoff +16 more
TL;DR: This work discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a 2–3 year timeframe with over 90% accuracy and may be sensitive to early neurodegeneration of preclinical Alzheimer’s disease.
Journal ArticleDOI
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Rik Ossenkoppele,Rik Ossenkoppele,Rik Ossenkoppele,Daniel R. Schonhaut,Daniel R. Schonhaut,Michael Schöll,Michael Schöll,Samuel N. Lockhart,Nagehan Ayakta,Nagehan Ayakta,Suzanne L. Baker,James P. O'Neil,Mustafa Janabi,Andreas Lazaris,Averill Cantwell,Jacob W. Vogel,Miguel Santos,Zachary A. Miller,Brianne M. Bettcher,Brianne M. Bettcher,Keith A. Vossel,Joel H. Kramer,Maria Luisa Gorno-Tempini,Bruce L. Miller,William J. Jagust,William J. Jagust,Gil D. Rabinovici,Gil D. Rabinovici +27 more
TL;DR: Results are consistent with and expand upon findings from post-mortem, animal and cerebrospinal fluid studies, and suggest that the pathological aggregation of tau is closely linked to patterns of neurodegeneration and clinical manifestations of Alzheimer's disease.
Journal ArticleDOI
Spreading of pathology in neurodegenerative diseases: a focus on human studies.
TL;DR: Recent evidence that supports the notion of neuron–neuron protein propagation is reviewed, with a focus on neuropathological and positron emission tomography imaging studies in humans.
References
More filters
Journal ArticleDOI
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
Christopher C. Rowe,Uwe Ackerman,William J Browne,Rachel S. Mulligan,Kerryn L Pike,Graeme O'Keefe,H. J. Tochon-Danguy,Gordon Chan,Salvatore U Berlangieri,Gareth Jones,Kerryn L Dickinson-Rowe,H Kung,Wei Zhang,Mei-Ping Kung,Daniel Skovronsky,Thomas Dyrks,Gerhard Holl,Sabine Krause,Matthias Friebe,Lutz Lehman,Stefanie Lindemann,Ludger Dinkelborg,Colin L. Masters,Victor L. Villemagne +23 more
TL;DR: F-BAY94-9172 PET discriminates between AD and FTLD or healthy controls and might facilitate integration of Abeta imaging into clinical practice.
Journal ArticleDOI
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Henry Engler,Anton Forsberg,Ove Almkvist,Gunnar Blomquist,Emma Larsson,Irina Savitcheva,Anders Wall,Anna Ringheim,Bengt Långström,Agneta Nordberg +9 more
TL;DR: Relatively stable PIB retention after 2 years of follow-up in patients with mild Alzheimer's disease suggests that amyloid deposition in the brain reaches a plateau by the early clinical stages of Alzheimer’s disease and therefore may precede a decline in rCMRGlc and cognition.
Journal ArticleDOI
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment : a phase 2 trial.
Rik Vandenberghe,Rik Vandenberghe,Koen Van Laere,Adrian Ivanoiu,Eric Salmon,Christine Bastin,Eric Triau,Steen G. Hasselbalch,Ian Law,Allan R. Andersen,Alex Korner,Lennart Minthon,Gaëtan Garraux,Natalie Nelissen,Guy Bormans,Christopher Buckley,Rikard Owenius,Lennart Thurfjell,Gill Farrar,David J. Brooks,David J. Brooks +20 more
TL;DR: Validation of the 18F‐labeled PIB derivative18F‐flutemetamol could significantly enhance access to in vivo β‐amyloid imaging technology.
Journal ArticleDOI
Amyloid imaging in mild cognitive impairment subtypes
David A. Wolk,David A. Wolk,Julie C. Price,Judy A. Saxton,Beth E. Snitz,Jeffrey A. James,Oscar L. Lopez,Howard J. Aizenstein,Ann D. Cohen,Lisa A. Weissfeld,Chester A. Mathis,William E. Klunk,Steven T. DeKosky +12 more
TL;DR: The amyloid imaging ligand Pittsburgh Compound B (PiB) was utilized to determine the presence of Alzheimer's disease pathology in different mild cognitive impairment (MCI) subtypes and to relate increased PiB binding to other markers of early AD and longitudinal outcome.
Journal ArticleDOI
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
Brian J. Bacskai,Matthew P. Frosch,Stefanie H. Freeman,Scott B. Raymond,Jean C. Augustinack,Keith A. Johnson,Michael C. Irizarry,William E. Klunk,Chester A. Mathis,Steven T. DeKosky,Steven M. Greenberg,Bradley T. Hyman,John H. Growdon +12 more
TL;DR: In this paper, a 76-year-old man with a clinical diagnosis of dementia with Lewy bodies underwent fluorodeoxyglucose 18 F and Pittsburgh compound B positron emission tomographic brain scans.
Related Papers (5)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E. Klunk,Henry Engler,Agneta Nordberg,Yanming Wang,G. Blomqvist,Daniel P. Holt,Mats Bergström,Irina Savitcheva,Guo Feng Huang,Sergio Estrada,Birgitta Ausén,Manik L. Debnath,Julien Barletta,Julie C. Price,Johan Sandell,Brian J. Lopresti,Anders Wall,Pernilla Koivisto,Gunnar Antoni,Chester A. Mathis,Bengt Långström +20 more
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark,Julie A. Schneider,Barry J. Bedell,Thomas G. Beach,Warren B. Bilker,Mark A. Mintun,Michael J. Pontecorvo,Franz Hefti,Alan Carpenter,Matthew Flitter,Michael J. Krautkramer,Hank F. Kung,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Eric M. Reiman,Simone P. Zehntner,Daniel Skovronsky +19 more
Imaging beta-amyloid burden in aging and dementia.
Christopher C. Rowe,Steven Ng,Uwe Ackermann,Sylvia J. Gong,Kerryn E. Pike,Gregory Raymond Savage,Tiffany F. Cowie,Kerryn L Dickinson,Paul Maruff,David Darby,Clare Smith,Michael Woodward,John Merory,Henri Tochon-Danguy,Graeme O'Keefe,William E. Klunk,Chett A Mathis,Julie C. Price,Colin L. Masters,Colin L. Masters,Victor L. Villemagne,Victor L. Villemagne +21 more